• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glaukos Corp.

Glaukos rises on Street-beating Q4, 2018 earnings

February 28, 2019 By Fink Densford

Glaukos logo

Shares in Glaukos (NYSE:GKOS) rose today after the ophthalmological-focused medical device maker posted fourth quarter and full year 2018 earnings that topped expectations on Wall Street. The San Clemente, Calif.-based company posted profits of approximately $1.8 million, or 4¢ per share, on sales of approximately $54.1 million for the three months ended December 31, for bottom-line […]

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Glaukos Corp.

Glaukos inks R&D deal for glaucoma therapy

August 6, 2018 By Sarah Faulkner

Glaukos logo

Glaukos (NYSE:GKOS) has inked a research & development deal with Japanese biotech D. Western Therapeutics Institute to develop an intraocular glaucoma therapy. Glaukos and DWTI plan to evaluate products from the biotech’s compound library, as well as potentially synthesize new compounds as a part of the collaboration. According to the terms of the agreement, DWTI is slated […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Glaukos Corp.

Glaukos touts Ph2 glaucoma trial for drug-eluting intraocular implant

January 10, 2018 By Sarah Faulkner

Glaukos logo

Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Glaukos Corp.

Glaukos touts iStent study with topical travoprost

June 21, 2017 By Sarah Faulkner

Glaukos logo

Glaukos (NYSE:GKOS) touted data today from a 53-patient glaucoma study showing that its iStent device combined with topical travoprost reduced mean intraocular pressure by 35% after 18 months of follow-up. The company’s flagship device is designed to lessen IOP by restoring the natural outflow of aqueous humor through the conventional pathway in a patient’s eye. […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Glaukos Corp.

Glaukos shares tumble despite Q1 beat

May 4, 2017 By Sarah Faulkner

Glaukos logo

Shares in Glaukos (NYSE:GKOS) fell -10% today after the ophthalmic medtech company beat expectations on Wall Street with its 1st quarter results. The San Clemente, Calif.-based company posted profits of $878,000, or 2¢ per share, on sales of $35.9 million for the 3 months ended March 31, for bottom-line loss of -2% on sales growth of […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Glaukos Corp.

Glaukos drops $6m on Dose Medical’s IOP sensor system

April 13, 2017 By Sarah Faulkner

Glaukos logo

Glaukos (NYSE:GKOS) said today that it acquired Dose Medical‘s intraocular pressure sensor system assets for $5.5 million in cash, plus $9.5 million contingent upon development, clinical and regulatory milestones. The Dose Medical IOP sensor system includes a micro-invasive ocular implant that captures and stores a glaucoma patient’s short-interval IOP measurements. The system transmits data to […]

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: Dose Medical, Glaukos Corp.

Teva Pharma CEO Vigodman steps down | Personnel Moves, February 7, 2017

February 7, 2017 By Fink Densford

Teva Pharmaceutical

Teva Pharmaceuticals (NYSE:TEVA) said this week that CEO Erez Vigodman has stepped down from their position at the head of the world’s biggest generic drugmaker. Vigodman’s exit from the company will take effect immediately, with board chair Yitzhak Peterburg taking on the interim role of chief exec. Israel-based Teva has seen shares plummet after a series of […]

Filed Under: Business/Financial News Tagged With: Endologix, Glaukos Corp., Glucotrack, Inflexxion, Medacta, Teva Pharmaceuticals, Titan Medical

Glaukos touts 3-year iStent study data

January 20, 2016 By Fink Densford

Glaukos (NYSE:GKOS) said today data from a 3-year study of its iStent Trabecular micro-bypass stent indicated that it, along with cataract surgery, lowered mean intraocular pressure 36% and reduced mean glaucoma medications by 86% 3 years post-surgery. The study reported a mean IP of 14.99 mmHg in 39 patients monitored after treatment for 3 years, compared […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Glaukos Corp.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS